- Home
- ESEA vs INBX Comparison
ESEA vs INBX Comparison
Compare ESEA & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | INBX |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.9M | 430.2M |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ESEA | INBX |
|---|---|---|
| Price | $53.71 | $88.53 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $62.00 | N/A |
| AVG Volume (30 Days) | 36.2K | ★ 245.4K |
| Earning Date | 11-18-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | ★ 6.77 | N/A |
| EPS | ★ 17.38 | N/A |
| Revenue | ★ $223,794,428.00 | $1,400,000.00 |
| Revenue This Year | $10.05 | $563.00 |
| Revenue Next Year | N/A | $230.77 |
| P/E Ratio | $3.11 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $26.30 | $10.81 |
| 52 Week High | $66.00 | $94.47 |
Technical Indicators
Market Signals| Indicator | ESEA | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 36.38 | 58.68 |
| Support Level | $54.90 | $74.80 |
| Resistance Level | $58.90 | $94.47 |
| Average True Range (ATR) | 2.53 | 6.40 |
| MACD | -0.75 | -1.07 |
| Stochastic Oscillator | 11.85 | 59.63 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.